Outlook Therapeutics announced that its ONS-5010 drug for wet age-related macular degeneration (AMD) did not meet the primary endpoint in the NORSE EIGHT clinical trial. Despite this setback, the company plans to resubmit its marketing application to the FDA in Q1 2025 based on ongoing data analysis and the drug’s favorable safety profile. The stock price has fallen significantly following the announcement.